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The remarkable clinical efficacy of crizotinib has quickly established anaplastic lym-phoma kinase (ALK) positivity as a key molecular feature in non–small-cell lung can-
cer (NSCLC).1–3 Together with the efficacy of epidermal growth factor receptor (EGFR) 
inhibitors in EGFR mutant disease, thoracic oncologists have become hungry for new 
molecular subtypes of NSCLC to identify and control with novel targeted therapies.4,5 Yet, 
a series of recent case reports in this journal remind us that significant health gains could 
be achieved in advanced NSCLC without the need for new targets. Specifically, tremendous 
progress could be made if we could just inhibit the molecular targets that we already know 
are important when those targets are located within the central nervous system (CNS).
Both Gandhi et al.6 and Maillet et al.7 report cases of ALK+ NSCLC responding to 
crizotinib outside the CNS, but progressing within the CNS. In a recent retrospective analy-
sis, the lifetime incidence of brain metastases in ALK+ lung cancer appeared similar in 
patients that either received or never received crizotinib, suggesting that crizotinib was not 
altering the natural history of the disease in the CNS.8 Consistent with this, and with these 
case reports, 13 of 28 ALK+ patients (46%) first progressed on crizotinib within the CNS, 
with 85% having ongoing extra-CNS disease control at the time.9 One potential explanation 
comes from the pharmacokinetic analyses of a single ALK+ patient progressing within the 
CNS. Five hours after taking 250 mg, the cerebrospinal fluid (CSF) crizotinib concentra-
tion was 0.0014 μmol/L with the CSF to plasma ratio only 0.0026.10 Put another way, the 
CSF levels in this patient were more than 170-fold lower than the concentration required 
for 50% growth inhibition in an ALK+ cell line in vitro.10 If the CNS really is crizotinib’s 
Achilles’ heel, then routine surveillance of the CNS should probably be considered for all 
crizotinib patients, although, in the absence of detailed data, the optimal frequency of this 
surveillance remains uncertain.
When CNS disease is detected, it may be treatable with radiotherapy. Radiotherapy to 
sites of progression, in conjunction with continuing the crizotinib was permitted in the early 
crizotinib trials.1,9 Although no randomized study has yet addressed the benefit of ongoing 
crizotinib post-CNS progression, in the face of extra-CNS disease control retrospective 
data suggest the inhibitor should not be stopped. When patients with either EGFR mutant 
or ALK+ disease and isolated CNS progression on erlotinib or crizotinib, respectively, 
received brain radiotherapy and the relevant inhibitor was kept going, further progression 
took more than 7 months to occur.9 As radiotherapy may increase the local permeability of 
the blood–brain barrier, there is also the possibility that the same inhibitor may be more 
beneficial in the CNS postradiation than it was preirradiation.11 Consistent with this, Kaneda 
et al.12 describe the seemingly exceptional case of an ALK+ patient with progression in a 
previously irradiated CNS lesion which then responded to crizotinib. Similarly, standard 
doses of crizotinib produced a response in a mesenchymal epithelial transition factor 
(MET)-amplified glioblastoma, approximately 5 months after prior radiotherapy.13
If CNS progression on crizotinib primarily reflects inadequate drug exposures, then 
another way of getting ALK+ CNS disease back under control would be to get drugs active 
against crizotinib-naive cancer into the CNS. An intrathecal formulation of crizotinib has 
been discussed with Pfizer, but has not yet been prioritized for clinical development. In 
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terms of other options, Gandhi et al.6 reported a prolonged 
CNS response using a combination of high-dose pemetrexed 
(900 mg/m2 q21 days) with high-dose continuous crizotinib 
(600 mg QD). However, although this case demonstrates that 
systemically active chemotherapy could be tried in the event 
of CNS progression, and ALK+ disease does seem more sen-
sitive to pemetrexed than to other cytotoxics, it is unclear 
which, if any, of the details of their combination regimen 
can be recommended.3 For example, pemetrexed at standard 
doses is also known to have activity in NSCLC CNS metas-
tases.14 In addition, although we do not know that the previ-
ously described CSF levels of crizotinib are representative, if 
they are, then increasing the crizotinib dose by only two- to 
threefold is highly unlikely to have achieved active CNS lev-
els.10 Arguably, the greatest promise for treating ALK+ dis-
ease within the CNS comes from the second-generation ALK 
inhibitors. Both LDK378 and AP26113 have now reported 
CNS responses within their early phase studies.15,16 Although 
this offers some hope to ALK+ patients, it is also important to 
recognize that no data have yet been presented on either the 
denominator of CNS disease to assess the reliability of these 
CNS responses, or their duration.
Discussing the clinical data that is, or is not, available 
brings us face to face with some of the major issues currently 
limiting progress in the treatment of NSCLC metastatic to 
the CNS. If these second-generation inhibitor studies had 
excluded all patients with CNS disease, then this early hint of 
CNS efficacy—a potential key differentiator from crizotinib—
would have been missed. Yet, unfortunately, many studies of 
novel agents still routinely exclude patients with asymptom-
atic and/or untreated parenchymal or leptomeningeal CNS 
disease. Although the assessment of responses in leptomen-
ingeal disease remains difficult, the Response Assessment in 
Neuro-Oncology group has now developed guidelines for the 
assessment of parenchymal metastases within clinical trials.17 
In a disease with such a high lifetime incidence of CNS dis-
ease, it also remains surprising that baseline and on therapy 
CNS imaging is not mandated or standardized within many 
lung cancer studies. When there is a lack of knowledge about 
whether a new drug penetrates into the CNS, the best way to 
determine this is going to be to formally look for CNS activity 
whenever extra-CNS activity is expected. If there are serious 
concerns that patients with CNS disease will adversely influ-
ence the efficacy signal of a new drug in a trial, then a stand-
alone CNS cohort at the recommended phase II dose could 
reasonably become a part of routine early drug development. 
Alternatively, if using local therapies for isolated CNS pro-
gression and continuing drug treatment becomes more widely 
accepted, then it may become standard practice to capture 
not just overall progression-free survival, but both CNS and 
extra-CNS progression-free survival values as well, ultimately 
allowing us to compare these between drugs.9,17 Modifying 
our clinical trial designs to reliably capture CNS-related infor-
mation is a straightforward strategy we could immediately 
adopt to begin directly addressing CNS metastases in the era 
of molecular oncology. Aiming at any target across the blood–
brain barrier will become much easier once we start to do it 
with our eyes appropriately open.
REFERENCES
 1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib 
in patients with ALK-positive non-small-cell lung cancer: updated results 
from a phase 1 study. Lancet Oncol 2012;13:1011–1019.
 2. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study 
with crizotinib in advanced ALK-positive non-small cell lung cancer 
(NSCLC). ASCO Meeting Abstracts 2012;30(15_suppl): 7533.
 3. Shaw AT, Varghese AM, Solomon BJ, et al. Pemetrexed-based chemother-
apy in patients with advanced, ALK-positive non-small cell lung cancer. 
Ann Oncol 2013;24:59–66.
 4. Kris MG, Johnson BE, Kwiatkowski DJ, et al: Identification of driver 
mutations in tumor specimens from 1,000 patients with lung adenocar-
cinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC). 2011 
ASCO Annual Meeting. Abstract CRA7506.
 5. Bunn PA Jr, Hirsch FR, Doebele RC, Camidge DR, Varella-Garcia M, 
Franklin W. Biomarkers are here to stay for clinical research and standard 
care. J Thorac Oncol 2010;5:1113–1115.
 6. Gandhi L, Drappatz J, Ramaiya NH, Otterson GA. High-dose pemetrexed 
in combination with high-dose crizotinib for the treatment of refractory 
CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac 
Oncol 2013;8:e3–e5.
 7. Maillet D, Martel-Lafay I, Arpin D, et al. Ineffectiveness of crizotinib on 
brain metastases in two cases of lung adenocarcinoma with EML4-ALK 
rearrangement. J Thorac Oncol 2013;8:e30–e31.
 8. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall 
survival in patients with advanced non-small-cell lung cancer harbour-
ing ALK gene rearrangement: a retrospective analysis. Lancet Oncol 
2011;12:1004–1012.
 9. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oli-
goprogressive disease prolongs disease control by tyrosine kinase inhibi-
tors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 
2012;7:1807–1814.
 10. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of 
the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 
2011;29:e443–e445.
 11. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann 
V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered 
in HER2-positive breast cancer patients with brain metastases and impair-
ment of blood-brain barrier. Anticancer Drugs 2007;18:23–28.
 12. Kaneda H, Okamoto I, Nakagawa K. Rapid response of brain metastasis 
to crizotinib in a patient with ALK rearrangement-positive non-small cell 
lung cancer. J Thorac Oncol 2013;8:e32–e33.
 13. Chi AS, Batchelor TT, Kwak EL, et al. Rapid radiographic and clinical 
improvement after treatment of a MET-amplified recurrent glioblas-
toma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 
2012;30:e30–e33.
 14. Bearz A, Garassino I, Tiseo M, et al. Activity of pemetrexed on brain metas-
tases from non-small cell lung cancer. Lung Cancer 2010;68:264–268.
 15. Mehra R, Camidge DR, Sharma S, et al. First-in-human phase I study of 
the ALK inhibitor LDK378 in advanced solid tumors. ASCO Proc 2012; 
3007.
 16. Gettinger S, Weiss GJ, Salgia R, et al. A first-in-human dose-finding study 
of the ALK/EGFR inhibitor AP26113 in patients with advanced malig-
nancies. ESMO 37th Annual Meeting 2012; Abstract 4390.
 17. Lin NU, Lee EQ, Aoyama H, et al. Response assessment in neuro-oncol-
ogy (A Report of the RANO Group): challenges relating to solid tumor 
brain metastases in clinical trials, part 1: patient population, response, and 
progression (Submitted).
